BioSpace News Archive

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Gregory Schultz, Ph.D., has been appointed as a Scientific Advisor. Dr. Schultz is the Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. Throughout his career, he has conducted research focusing on the molecular and cellular regulators of normal wound healing and developing t

- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2020 and provided a company update. “During the second quarter, we continued to execute on key strategic and operational objectives, despite the challenges presented by the COVID-19 pandemic,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Importantly, we initiated the DARE-BVFRE

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines [12-August-2020] SINGAPORE and SAN DIEGO , Aug. 12, 2020 /PRNewswire/ -- ImmunoScape ( www.ImmunoScape.com ), a biotech firm enabling unprecedented insights into the human immune sys

Northwell Health today joined Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, in announcing a long-term strategic partnership to transform the quality of patient care by using data and analytics

Portal Innovations, LLC, a national life sciences, medtech and bioinformatics start-up incubator today announced that Brian Yoor is joining the Company as Chairman and Senior Operations Advisor. Partnering closely with founder and CEO, John Flavin he will leverage his deep experience leading diverse and multi-functional teams to help Portal build a world

ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as September 2020

Biomerica Inc. (NASDAQ: BMRA ) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that offers a revolutionary new way to treat patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application #16/385,322 contains numerous claims that broadl

Phase III randomized placebo-controlled study in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of complete disease remission on minimal oral corticosteroids (OCS) agreed to with the FDA. Treatment arms will be tapered to minimal OCS and an important secondary endpoint is reduction in cumulative OCS on nomacopan as high dose OCS are regarded as unsafe in this vulnerable patient population. BP Phase III trial expected to start H1 2021 Nomacopan has b

- Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease with Lead Drug Candidate, PTI-125, Expected to be Announced September 2020 - - SavaDx Demonstrates Direct Evidence of Target Engagement & Treatment Effects - - Open-label Study Of PTI-125 Reaches >50% Enrollment - AUSTIN, Texas, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results f

Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273.